## Andrzej Przybylski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6289148/publications.pdf

Version: 2024-02-01

58	640	840776 <b>11</b>	610901
papers	citations	h-index	g-index
60	60	60	1141
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Home-based telemonitored Nordic walking training is well accepted, safe, effective and has high adherence among heart failure patients, including those with cardiovascular implantable electronic devices: a randomised controlled study. European Journal of Preventive Cardiology, 2015, 22, 1368-1377.	1.8	128
2	Subacute cardiac perforations associated with active fixation leads. Europace, 2008, 11, 206-212.	1.7	80
3	Implantable Cardioverterâ€Defibrillator in Patients With Hypertrophic Cardiomyopathy: Efficacy and Complications of the Therapy in Longâ€Term Followâ€up. Journal of Cardiovascular Electrophysiology, 2010, 21, 883-889.	1.7	67
4	Ablation of Severe Drugâ€Resistant Tachyarrhythmia During Pregnancy. Journal of Cardiovascular Electrophysiology, 2010, 21, 877-882.	1.7	67
5	Patients' knowledge and attitudes regarding living with implantable electronic devices: results of a multicentre, multinational patient survey conducted by the European Heart Rhythm Association. Europace, 2018, 20, 386-391.	1.7	35
6	Magnetic resonance imaging assessment of intraventricular dyssynchrony and delayed enhancement as predictors of response to cardiac resynchronization therapy in patients with heart failure of ischaemic and non-ischaemic etiologies. European Journal of Radiology, 2012, 81, 2639-2647.	2.6	28
7	Long-term follow-up of children and young adults treated with implantable cardioverter-defibrillator: the authors' own experience with optimal implantable cardioverter-defibrillator programming. Europace, 2010, 12, 1245-1250.	1.7	22
8	Fuzzy logic-based diagnostic algorithm for implantable cardioverter defibrillators. Artificial Intelligence in Medicine, 2014, 60, 113-121.	6.5	17
9	Anxiety and depression among the patients with frequent implantable cardioverter–defibrillator discharges. International Journal of Cardiology, 2009, 132, e80-e81.	1.7	15
10	Post heart transplant extraction of the abandoned fragments of pacing and defibrillation leads: proposed management algorithm. Kardiologia Polska, 2013, 71, 159-163.	0.6	14
11	Clinical Validation and Comparison of Alternative Methods for Evaluation of Entrainment Mapping. Journal of Cardiovascular Electrophysiology, 2009, 20, 741-748.	1.7	13
12	Ventricular fibrillation risk factors in over one thousand patients with accessory pathways. International Journal of Cardiology, 2013, 167, 525-530.	1.7	13
13	LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies. BMC Medical Genetics, 2013, 14, 55.	2.1	11
14	Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy – dilemmas and difficulties. Kardiologia Polska, 2005, 63, 391-7; discussion 398.	0.6	11
15	Endocardial Lead Extraction in the Polish Registry – clinical practice versus current Heart Rhythm Society consensus. Archives of Medical Science, 2014, 2, 258-265.	0.9	10
16	Palliative care for people living with cardiac disease. Kardiologia Polska, 2020, 78, 364-373.	0.6	8
17	The effectiveness of transvenous leads extractions implanted more than 10 years before. Cardiology Journal, 2014, 21, 419-424.	1.2	8
18	Long-term temporary pacing with an active fixation lead. Kardiologia Polska, 2015, 73, 1304-1309.	0.6	7

#	Article	IF	CITATIONS
19	The effect of sacubitril / valsartan on the occurrence of ventricular arrhythmia and the risk of sudden cardiac death in patients with chronic heart failure with reduced left ventricular ejection fraction. Expert opinion of the Heart Rhythm and Heart Failure Sections of the Polish Cardiac Society.  Kardiologia Polska, 2019, 77, 987-993.	0.6	6
20	Patients with cardiac implantable electronic devices undergoing radiotherapy in Poland. Expert opinion of the Heart Rhythm Section of the Polish Cardiac Society and the Polish Society of Radiation Oncology. Kardiologia Polska, 2019, 77, 1106-1116.	0.6	6
21	Verification of implantable cardioverter defibrillator (ICD) interventions by nonlinear analysis of heart rate variability? preliminary results. Europace, 2004, 6, 617-624.	1.7	5
22	Percutaneous stellate ganglion block as an adjunctive therapy in the treatment of incessant ventricular tachycardia. Kardiologia Polska, 2018, 76, 1018-1020.	0.6	5
23	Causes of redo procedures in patients with an implantable cardioverter-defibrillator-long-term follow-up results. Kardiologia Polska, 2007, 65, 893-8; discussion 899.	0.6	5
24	Safety of nerve conduction studies in patients with implantable cardioverter–defibrillators. Clinical Neurophysiology, 2012, 123, 211-213.	1.5	4
25	Reduction of the Inappropriate ICD Therapies by Implementing a New Fuzzy Logic–Based Diagnostic Algorithm. Annals of Noninvasive Electrocardiology, 2013, 18, 457-466.	1.1	4
26	Reduced Albuminuria and Potassemia Indicate Early Renal Repair Processes after Resynchronization Therapy in Cardiorenal Syndrome Type 2. Cardiology Research and Practice, 2020, 2020, 1-10.	1.1	4
27	QRS complex widening as a predictor of appropriate implantable cardioverter-defibrillator (ICD) therapy and higher mortality risk in primary prevention ICD patients. Kardiologia Polska, 2012, 70, 360-8.	0.6	4
28	Usefulness of the Evolution mechanical dilator sheath for endocardial lead extraction – preliminary results. Postepy W Kardiologii Interwencyjnej, 2010, 2, 59-65.	0.2	3
29	Regaining venous access for implantation of a new lead. Postepy W Kardiologii Interwencyjnej, 2013, 1, $16-21$ .	0.2	3
30	Experiences and Opinions of Patients and Their Relatives to Family Presence During Adult Resuscitation in Poland: Quantitative Research. Patient Preference and Adherence, 2020, Volume 14, 227-234.	1.8	3
31	Expert opinion of the Working Group on Leadless Pacing appointed by the National Consultant in Cardiology and the Board of the Heart Rhythm Section of the Polish Cardiac Society. Kardiologia Polska, 2021, 79, 604-608.	0.6	3
32	A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. Cardiology Journal, 2021, 28, 607-614.	1.2	3
33	Electrotherapy and electrophysiology procedures during the coronavirus disease 2019 pandemic: an opinion of the Heart Rhythm Section of the Polish Cardiac Society (with an update). Kardiologia Polska, 2020, 78, 488-492.	0.6	3
34	Implantable cardioverterâ€defibrillator therapy in a 34â€yearâ€old patient with eating disorders and after the third sudden cardiac arrest. International Journal of Eating Disorders, 2015, 48, 253-257.	4.0	2
35	Implantable cardiac defibrillator events in patients with arrhythmogenic right ventricular cardiomyopathy. Heart, 2022, 108, 22-28.	2.9	2
36	Patients with heart failure and an implanted cardioverter-defibrillator during the COVID-19 pandemic: insights from a multicentre registry in Poland. Kardiologia Polska, 2021, 79, 562-565.	0.6	2

3

#	Article	IF	CITATIONS
37	Evolution of implantation technique and indications for a subcutaneous cardioverter-defibrillator over 7 years of experience in Poland. Kardiologia Polska, 2021, 79, 1016-1018.	0.6	2
38	Utilization of Subcutaneous Cardioverter-Defibrillator in Poland and Europe–Comparison of the Results of Multi-Center Registries. International Journal of Environmental Research and Public Health, 2021, 18, 7178.	2.6	2
39	Lead extraction: The road to successful cardiac resynchronization therapy. Cardiology Journal, 2015, 22, 188-193.	1.2	2
40	Early stage of left atrium remodelling predicts better outcome in long-term follow-up of atrial fibrillation ablation. Kardiologia Polska, 2014, 72, 925-933.	0.6	2
41	Factors determining the choice between subcutaneous or transvenous implantable cardioverter-defibrillators in Poland in comparison with other European countries: a sub-study of the European Heart Rhythm Association prospective survey. Kardiologia Polska, 2018, 76, 1507-1515.	0.6	2
42	Safety of antiviral and anti-inflammatory drugs prolonging QT interval in patients with coronavirus disease 2019: an opinion of the Heart Rhythm Section of the Polish Cardiac Society. Kardiologia Polska, 2020, 78, 493-497.	0.6	2
43	Therapeutic challenges and management of heart failure during pregnancy (part I). Medical Science Monitor, 2012, 18, CQ5-CQ7.	1.1	1
44	Subepicardial aneurysm after blunt chest trauma: a life-saving complication?. Kardiologia Polska, 2020, 78, 161-162.	0.6	1
45	Towards Prediction of Heart Arrhythmia Onset Using Machine Learning. Lecture Notes in Computer Science, 2020, , 376-389.	1.3	1
46	Unsuccessful left ventricular lead implantation in two first-degree relatives. Is the coronary venous anatomy similar in both cases?. Europace, 2009, 11, 1718-1720.	1.7	0
47	Deleterious effect of unintentional pacing from the middle cardiac vein in a patient with congenitally corrected transposition of the great arteries and ventricular septal defect. The beneficial effect of cardiac resynchronization therapy after heart surgery. Journal of Interventional Cardiac Electrophysiology, 2009, 24, 67-70.	1.3	0
48	Cardiac resynchronisation therapy – clinical perspectives. Postepy W Kardiologii Interwencyjnej, 2010, 3, 126-133.	0.2	0
49	New methods in diagnostic and therapy New applications of cardiovascular magnetic resonance to guide cardiac resynchronization therapy. Postepy W Kardiologii Interwencyjnej, 2012, 3, 234-243.	0.2	0
50	Effectiveness of antitachycardia pacing therapy after primary prophylaxis implantation of implantable defibrillators in coronary artery disease patients. Advances in Medical Sciences, 2014, 59, 161-165.	2.1	0
51	PO193MEASUREMENTS OF SERUM CREATININE AND EGFR IN PATIENTS WITH CHRONIC CARDIORENAL SYNDROME TYPE 2 ARE INSUFFICIENT TO ASSESS RENAL RESPONSES TO RESYNCHRONIZATION THERAPY DURING A TREE-MONTH FOLLOW-UP. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
52	Safety issues in selected patients implanted with Boston Scientific EMBLEM subcutaneous cardioverter defibrillator systems. Kardiologia Polska, 2021, 79, 223-224.	0.6	0
53	Multicenter Registry of Subcutaneous Cardioverter-Defibrillator Implantations â€" preliminary report. Kardiologia Polska, 2021, 79, 697-699.	0.6	0
54	Therapeutic challenges and management of heart failure during pregnancy (part 2). Medical Science Monitor, 2012, 18, CQ9-CQ13.	1.1	0

#	Article	IF	CITATIONS
55	Occurrence and extraction of implantable cardioverter-defibrillator leads with conductor externalization. Cardiology Journal, 2018, 25, 221-228.	1.2	0
56	Classification of rare cardiovascular diseases and disorders: challenges in categorisation of different diseases. Journal of Rare Cardiovascular Diseases, $2019, 3, \ldots$	0.0	0
57	Experts of the Heart Rhythm Section of the Polish Cardiac Society: opinion on the use of wearable cardioverter-defibrillators in Poland. Kardiologia Polska, 2019, 77, 238-243.	0.6	O
58	Predictors of arrhythmia other than QT interval prolongation and the use of $\hat{l}^2$ -blocker therapy in the coronavirus disease 2019 pandemic. Authors' reply. Kardiologia Polska, 2020, 78, 796-797.	0.6	0